177 related articles for article (PubMed ID: 24151445)
1. TNF-α -857C>T genotype is predictive of clinical response after treatment with definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Omatsu H; Kuwahara A; Yamamori M; Fujita M; Okuno T; Miki I; Tamura T; Nishiguchi K; Okamura N; Nakamura T; Azuma T; Hirano T; Ozawa K; Hirai M
Int J Med Sci; 2013; 10(12):1755-60. PubMed ID: 24151445
[TBL] [Abstract][Full Text] [Related]
2. TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Kuwahara A; Yamamori M; Fujita M; Okuno T; Tamura T; Kadoyama K; Okamura N; Nakamura T; Sakaeda T
J Exp Clin Cancer Res; 2010 Jul; 29(1):100. PubMed ID: 20646319
[TBL] [Abstract][Full Text] [Related]
3. VEGF -634C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Tamura T; Kuwahara A; Yamamori M; Nishiguchi K; Nakamura T; Okuno T; Miki I; Manabe Y; Sakaeda T
Int J Med Sci; 2012; 9(10):833-7. PubMed ID: 23155356
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Minegaki T; Kuwahara A; Yamamori M; Nakamura T; Okuno T; Miki I; Omatsu H; Tamura T; Hirai M; Azuma T; Sakaeda T; Nishiguchi K
Int J Med Sci; 2014; 11(4):321-6. PubMed ID: 24578608
[TBL] [Abstract][Full Text] [Related]
5. Effects of plasma concentrations of 5-fluorouracil on long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Kuwahara A; Yamamori M; Kadoyama K; Nishiguchi K; Nakamura T; Miki I; Tamura T; Okuno T; Omatsu H; Sakaeda T
J Exp Clin Cancer Res; 2011 Oct; 30(1):94. PubMed ID: 21970688
[TBL] [Abstract][Full Text] [Related]
6. VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients.
Sakaeda T; Yamamori M; Kuwahara A; Hiroe S; Nakamura T; Okumura K; Okuno T; Miki I; Chayahara N; Okamura N; Tamura T
Ther Drug Monit; 2008 Aug; 30(4):497-503. PubMed ID: 18641541
[TBL] [Abstract][Full Text] [Related]
7. Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.
Kuwahara A; Yamamori M; Nishiguchi K; Okuno T; Chayahara N; Miki I; Tamura T; Inokuma T; Takemoto Y; Nakamura T; Kataoka K; Sakaeda T
Int J Med Sci; 2009 Sep; 6(6):305-11. PubMed ID: 19834547
[TBL] [Abstract][Full Text] [Related]
8. THRB genetic polymorphisms can predict severe myelotoxicity after definitive chemoradiotherapy in patients with esophageal squamous cell carcinoma.
Miki I; Nakamura T; Kuwahara A; Yamamori M; Nishiguchi K; Tamura T; Okuno T; Omatsu H; Mizuno S; Hirai M; Azuma T; Sakaeda T
Int J Med Sci; 2012; 9(9):748-56. PubMed ID: 23136537
[TBL] [Abstract][Full Text] [Related]
9. Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese.
Okuno T; Tamura T; Yamamori M; Chayahara N; Yamada T; Miki I; Okamura N; Kadowaki Y; Shirasaka D; Aoyama N; Nakamura T; Okumura K; Azuma T; Kasuga M; Sakaeda T
Am J Clin Oncol; 2007 Jun; 30(3):252-7. PubMed ID: 17551301
[TBL] [Abstract][Full Text] [Related]
10. Association of TNF-α gene alterations (c.-238G>A, c.-308G>A, c.-857C>T, c.-863C>A) with primary glaucoma in north Indian cohort.
Passan S; Goyal S; Bhat MA; Singh D; Vanita V
Gene; 2019 Aug; 709():25-35. PubMed ID: 31132515
[TBL] [Abstract][Full Text] [Related]
11. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
[TBL] [Abstract][Full Text] [Related]
13. A phase IIa study of rhLTα-Da in combination with cisplatin and fluorouracil for patients with metastatic esophageal squamous cell carcinoma or gastric adenocarcinoma.
Wang FH; Wang Y; Chen ZD; Chen JH; Qin FZ; Jiang WQ; Li YH
Med Oncol; 2016 Nov; 33(11):125. PubMed ID: 27743200
[TBL] [Abstract][Full Text] [Related]
14. Association of common polymorphisms in TNFA, NFkB1 and NFKBIA with risk and prognosis of esophageal squamous cell carcinoma.
Umar M; Upadhyay R; Kumar S; Ghoshal UC; Mittal B
PLoS One; 2013; 8(12):e81999. PubMed ID: 24324738
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-α gene 308G/A polymorphism is not associated with esophageal squamous cell carcinoma risk in Kazakh patients.
Cui XB; Wang DD; Zhang HY; Li TT; Jin TT; Peng H; Zhang SM; Wang B; Yu J; Liu CX; Yang L; Jin J; Li S; Jiang JF; Liang WH; Hu JM; Li SG; Wu CY; Chen YZ; Li F
Int J Clin Exp Pathol; 2015; 8(8):9293-9. PubMed ID: 26464679
[TBL] [Abstract][Full Text] [Related]
16. Effects of SLC31A1 and ATP7B polymorphisms on platinum resistance in patients with esophageal squamous cell carcinoma receiving neoadjuvant chemoradiotherapy.
Fujita K; Motoyama S; Sato Y; Wakita A; Nagaki Y; Minamiya Y; Miura M
Med Oncol; 2021 Jan; 38(1):6. PubMed ID: 33411033
[TBL] [Abstract][Full Text] [Related]
17. Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma.
Kuwahara A; Yamamori M; Nishiguchi K; Okuno T; Chayahara N; Miki I; Tamura T; Kadoyama K; Inokuma T; Takemoto Y; Nakamura T; Kataoka K; Sakaeda T
Int J Med Sci; 2010 Jan; 7(1):48-54. PubMed ID: 20151048
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
[TBL] [Abstract][Full Text] [Related]
19. Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.
Hu G; Wang Z; Wang Y; Zhang Q; Tang N; Guo J; Liu L; Han X
Drug Des Devel Ther; 2016; 10():2129-36. PubMed ID: 27445460
[TBL] [Abstract][Full Text] [Related]
20. Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy.
Zhao Z; Zhang Y; Wang X; Geng X; Zhu L; Li M
Cancer Med; 2020 Aug; 9(16):5881-5888. PubMed ID: 32627960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
